Sectors & IndustriesHealthcareMedical Instruments & Supplies

Best Medical Stocks to Buy Now (2026)

Top medical stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best medical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

Icu Medical (NASDAQ:ICUI) is the #1 top medical stock out of 51 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Icu Medical (NASDAQ:ICUI) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: C.

Icu Medical (NASDAQ:ICUI) has a Due Diligence Score of 27, which is -4 points lower than the medical industry average of 31. Although this number is below the industry average, our proven quant model rates ICUI as a "A".

ICUI passed 9 out of 33 due diligence checks and has average fundamentals. Icu Medical has seen its stock return 43.32% over the past year, overperforming other medical stocks by 40 percentage points.

Icu Medical has an average 1 year price target of $191.00, an upside of 13.25% from Icu Medical's current stock price of $168.65.

Icu Medical stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Icu Medical, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Haemonetics (NYSE:HAE) is the #2 top medical stock out of 51 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Haemonetics (NYSE:HAE) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Haemonetics (NYSE:HAE) has a Due Diligence Score of 27, which is -4 points lower than the medical industry average of 31. Although this number is below the industry average, our proven quant model rates HAE as a "A".

HAE passed 9 out of 33 due diligence checks and has average fundamentals. Haemonetics has seen its stock return 142.29% over the past year, overperforming other medical stocks by 139 percentage points.

Haemonetics has an average 1 year price target of $117.88, a downside of -1.6% from Haemonetics's current stock price of $119.79.

Haemonetics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Haemonetics, 37.5% have issued a Strong Buy rating, 50% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Infusystem Holdings (NYSEMKT:INFU) is the #3 top medical stock out of 51 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: C, Momentum: A, Sentiment: A, Safety: C, Financials: A, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 41, which is 10 points higher than the medical industry average of 31.

INFU passed 13 out of 33 due diligence checks and has strong fundamentals. Infusystem Holdings has seen its stock return 37.36% over the past year, overperforming other medical stocks by 34 percentage points.

Infusystem Holdings has an average 1 year price target of $20.00, an upside of 38.41% from Infusystem Holdings's current stock price of $14.45.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 11 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

Embecta (NASDAQ:EMBC) has an annual dividend yield of 4.88%, which is 4 percentage points higher than the medical industry average of 1.35%. Embecta's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Embecta's dividend has not shown consistent growth over the last 10 years.

Embecta's dividend payout ratio of 30.7% indicates that its high dividend yield is sustainable for the long-term.

Becton Dickinson & Co (NYSE:BDX) has an annual dividend yield of 2.12%, which is 1 percentage points higher than the medical industry average of 1.35%. Becton Dickinson & Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Becton Dickinson & Co's dividend has shown consistent growth over the last 10 years.

Becton Dickinson & Co's dividend payout ratio of 126.2% indicates that its dividend yield might not be sustainable for the long-term.

Utah Medical Products (NASDAQ:UTMD) has an annual dividend yield of 1.86%, which is 1 percentage points higher than the medical industry average of 1.35%. Utah Medical Products's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Utah Medical Products's dividend has shown consistent growth over the last 10 years.

Utah Medical Products's dividend payout ratio of 37.7% indicates that its dividend yield is sustainable for the long-term.

Medical stocks were up 1.47% in the last day, and up 1.43% over the last week. West Pharmaceutical Services was the among the top gainers in the medical instruments & supplies industry, gaining 3.23% yesterday.

West Pharmaceutical Services shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 GAAP EPS guidance above estimates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 36 points higher than the medical industry average of 21. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -51.73% in the past year. It has underperformed other stocks in the medical industry by -55 percentage points.

Bausch & Lomb (NYSE:BLCO) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch & Lomb has a valuation score of 14, which is -7 points higher than the medical industry average of 21. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates BLCO a Valuation Rating of "B".

Bausch & Lomb's stock has gained 31.87% in the past year. It has overperformed other stocks in the medical industry by 29 percentage points.

Envista Holdings (NYSE:NVST) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Envista Holdings has a valuation score of 57, which is 36 points higher than the medical industry average of 21. It passed 4 out of 7 valuation due diligence checks.

Envista Holdings's stock has gained 23.17% in the past year. It has overperformed other stocks in the medical industry by 20 percentage points.

43.24% of medical stocks rated by analysts are a buy right now. On average, analysts expect medical stocks to rise by 7.28% over the next year.

10.26% of medical stocks have a Zen Rating of A (Strong Buy), 20.51% of medical stocks are rated B (Buy), 58.97% are rated C (Hold), 7.69% are rated D (Sell), and 2.56% are rated F (Strong Sell).